Show simple item record

dc.contributor.authorJames, N
dc.contributor.authorSpears, M
dc.contributor.authorClarke, Noel W
dc.contributor.authorDearnaley, D
dc.contributor.authorMason, M
dc.contributor.authorParker, C
dc.contributor.authorRitchie, A
dc.contributor.authorRussell, J
dc.contributor.authorSchiavone, F
dc.contributor.authorAttard, G
dc.contributor.authorde Bono, J
dc.contributor.authorBirtle, A
dc.contributor.authorEngeler, D
dc.contributor.authorElliott, T
dc.contributor.authorMatheson, D
dc.contributor.authorO'Sullivan, J
dc.contributor.authorPudney, D
dc.contributor.authorSrihari, N
dc.contributor.authorWallace, J
dc.contributor.authorBarber, J
dc.contributor.authorSyndikus, I
dc.contributor.authorParmar, M
dc.contributor.authorSydes, M
dc.date.accessioned2016-01-06T15:25:45Zen
dc.date.available2016-01-06T15:25:45Zen
dc.date.issued2015-11-25en
dc.identifier.citationFailure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. 2015:1-10 JAMA Oncolen
dc.identifier.issn2374-2445en
dc.identifier.pmid26606329en
dc.identifier.doi10.1001/jamaoncol.2015.4350en
dc.identifier.urihttp://hdl.handle.net/10541/592999en
dc.description.abstractThe natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinical trial has assessed the role of RT in patients with node-positive (N+) M0 disease. The STAMPEDE Trial includes such individuals, allowing an exploratory multivariate analysis of the impact of radical RT.
dc.languageENGen
dc.rightsArchived with thanks to JAMA oncologyen
dc.titleFailure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial.en
dc.typeArticleen
dc.contributor.departmentWarwick Medical School, University of Warwick, Coventryen
dc.identifier.journalJAMA Oncologyen
html.description.abstractThe natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinical trial has assessed the role of RT in patients with node-positive (N+) M0 disease. The STAMPEDE Trial includes such individuals, allowing an exploratory multivariate analysis of the impact of radical RT.


This item appears in the following Collection(s)

Show simple item record